New Issue: Science’s Impossible Questions. Read Now

Cocaine's Newest Risks: Dying Skin and Compromised Immunity

A new drug contaminant is causing frightening outbreaks of blackened skin and low white blood cell counts

Join Our Community of Science Lovers!

To the list of cocaine’s many dangers, health officials have added at least one more: purpura, a rash caused by internal bleeding from small blood vessels. Two recent papers in major medical journals have documented cases of cocaine users showing up in emergency rooms with patches of blackened, dying skin on the ears, face, trunk or extremities. The condition causes scarring and sometimes requires reconstructive surgery. Noah Craft, a dermatologist at the Harbor-UCLA Medical Center who co-authored a paper on the condition published online by the Journal of the American Academy of Dermatology in June, says he now sees about one case per month: “It’s become almost routine.”

The cause of the outbreak is a veterinary deworming medication that has become the most common ingredient used to dilute, or cut, cocaine coming into the U.S. from South America. The drug, called levamisole, was once approved for cancer treatment but was later pulled because of its side effects. Three quarters of the cocaine bricks seized by the U.S. Drug Enforcement Administration now contain levamisole.

Equally worrying is another of its side effects: a sometimes fatal lowered count of white blood cells that are called neutrophils. Doctors suspect that both conditions are allergic reactions to the drug. In one disease, the body’s immune system attacks the skin; in the other, it attacks the bone marrow.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Traffickers may add levamisole to cocaine because it is cheaper than pure cocaine and may contribute to the cocaine high. Papers between the 1970s and 1990s, when levamisole was being suggested and then approved for medical use in the U.S., found it improved mood and caused insomnia and hyperalertness, effects that are similar to cocaine’s.

For now, the dea will not change how it pursues traffickers, says Barbara Carreno, an agency spokesperson. But doctors are learning to spot the skin rash quicker. Craft has added photos of his patients to a computerized alert system used by 1,300 hospitals nationwide.

Scientific American Magazine Vol 305 Issue 3This article was published with the title “Cocaine's Newest Risks: Dying Skin and Compromised Immunity” in Scientific American Magazine Vol. 305 No. 3 ()
doi:10.1038/scientificamerican092011-1rCUgLLAA6HqX52IZt4oPG

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe